4. Mereo BioPharma Group plc (NASDAQ:MREO)
Closing Share Price $0.3798
Daily Increase 3.52%
Market Cap $60.65 Million
Mereo BioPharma Group plc (NASDAQ: MREO) develops therapies for rare diseases. Its programs include treatments targeting bone disorders and lung disease, giving it a specialized position within biotechnology. These markets can involve substantial unmet medical needs, but development and regulatory requirements remain demanding.
The stock advanced 3.52% to $0.3798. Its low price produced a score of 9.27, enough for fourth place despite a comparatively modest daily increase. Reported market capitalization was approximately $60.65 million, underscoring the difference between the price of an individual share and the value assigned to the entire company.
The reported trailing net loss was approximately $28.10 million, with no trailing revenue figure displayed. Investors following rare-disease biotech stocks should assess clinical progress, regulatory developments, partnerships, and available funding. The ranking captures one session’s price behavior; it does not establish the probability of a successful drug-development outcome.
